Logo image of VRME

VERIFYME INC (VRME) Stock Fundamental Analysis

NASDAQ:VRME - Nasdaq - US92346X2062 - Common Stock - Currency: USD

0.7011  +0.01 (+0.88%)

After market: 0.701 0 (-0.01%)

Fundamental Rating

2

Taking everything into account, VRME scores 2 out of 10 in our fundamental rating. VRME was compared to 125 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of VRME have multiple concerns. VRME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year VRME has reported negative net income.
In the past year VRME had a positive cash flow from operations.
In the past 5 years VRME reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: VRME reported negative operating cash flow in multiple years.
VRME Yearly Net Income VS EBIT VS OCF VS FCFVRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

With a Return On Assets value of -23.80%, VRME is not doing good in the industry: 74.40% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -37.44%, VRME is doing worse than 72.00% of the companies in the same industry.
Industry RankSector Rank
ROA -23.8%
ROE -37.44%
ROIC N/A
ROA(3y)-36.52%
ROA(5y)-32.04%
ROE(3y)-56.82%
ROE(5y)-44.86%
ROIC(3y)N/A
ROIC(5y)N/A
VRME Yearly ROA, ROE, ROICVRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

With a Gross Margin value of 35.78%, VRME perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
VRME's Gross Margin has declined in the last couple of years.
VRME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.64%
GM growth 5Y-15.56%
VRME Yearly Profit, Operating, Gross MarginsVRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

3

2. Health

2.1 Basic Checks

VRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRME has more shares outstanding than it did 1 year ago.
VRME has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VRME is higher compared to a year ago.
VRME Yearly Shares OutstandingVRME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VRME Yearly Total Debt VS Total AssetsVRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

VRME has an Altman-Z score of -5.34. This is a bad value and indicates that VRME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.34, VRME is not doing good in the industry: 88.80% of the companies in the same industry are doing better.
VRME has a debt to FCF ratio of 5.68. This is a neutral value as VRME would need 5.68 years to pay back of all of its debts.
With a Debt to FCF ratio value of 5.68, VRME perfoms like the industry average, outperforming 57.60% of the companies in the same industry.
VRME has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, VRME is in line with its industry, outperforming 54.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 5.68
Altman-Z -5.34
ROIC/WACCN/A
WACC9.49%
VRME Yearly LT Debt VS Equity VS FCFVRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

VRME has a Current Ratio of 1.50. This is a normal value and indicates that VRME is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VRME (1.50) is worse than 72.80% of its industry peers.
VRME has a Quick Ratio of 1.49. This is a normal value and indicates that VRME is financially healthy and should not expect problems in meeting its short term obligations.
VRME has a Quick ratio (1.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.49
VRME Yearly Current Assets VS Current LiabilitesVRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

3

3. Growth

3.1 Past

The earnings per share for VRME have decreased strongly by -56.52% in the last year.
The Revenue has decreased by -4.37% in the past year.
The Revenue has been growing by 151.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-56.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-4.37%
Revenue growth 3Y203.02%
Revenue growth 5Y151.62%
Sales Q2Q%-22.64%

3.2 Future

Based on estimates for the next years, VRME will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.35% on average per year.
The Revenue is expected to decrease by -3.10% on average over the next years.
EPS Next Y44.75%
EPS Next 2Y22.07%
EPS Next 3Y16.35%
EPS Next 5YN/A
Revenue Next Year-18.14%
Revenue Next 2Y-6.88%
Revenue Next 3Y-3.1%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VRME Yearly Revenue VS EstimatesVRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
VRME Yearly EPS VS EstimatesVRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRME. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRME Price Earnings VS Forward Price EarningsVRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, VRME is valued a bit cheaper than the industry average as 69.60% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 24.88
EV/EBITDA N/A
VRME Per share dataVRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as VRME's earnings are expected to grow with 16.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y16.35%

0

5. Dividend

5.1 Amount

No dividends for VRME!.
Industry RankSector Rank
Dividend Yield N/A

VERIFYME INC

NASDAQ:VRME (5/20/2025, 8:00:02 PM)

After market: 0.701 0 (-0.01%)

0.7011

+0.01 (+0.88%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners8.76%
Inst Owner Change154.28%
Ins Owners19.03%
Ins Owner Change2.71%
Market Cap8.66M
Analysts85
Price Target1.66 (136.77%)
Short Float %0.62%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.4%
Min EPS beat(2)-114.75%
Max EPS beat(2)-40.06%
EPS beat(4)2
Avg EPS beat(4)-8.7%
Min EPS beat(4)-114.75%
Max EPS beat(4)69.04%
EPS beat(8)5
Avg EPS beat(8)1.08%
EPS beat(12)7
Avg EPS beat(12)-14.2%
EPS beat(16)10
Avg EPS beat(16)-11.47%
Revenue beat(2)1
Avg Revenue beat(2)-3.36%
Min Revenue beat(2)-8.55%
Max Revenue beat(2)1.84%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-8.55%
Max Revenue beat(4)1.84%
Revenue beat(8)2
Avg Revenue beat(8)-3.91%
Revenue beat(12)4
Avg Revenue beat(12)0.47%
Revenue beat(16)6
Avg Revenue beat(16)3.03%
PT rev (1m)0%
PT rev (3m)-27.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)15.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.13%
Revenue NY rev (1m)-14.29%
Revenue NY rev (3m)-22.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF 24.88
P/OCF 9.94
P/B 0.85
P/tB 10.06
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.03
FCFY4.02%
OCF(TTM)0.07
OCFY10.06%
SpS1.96
BVpS0.83
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.8%
ROE -37.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.78%
FCFM 1.44%
ROA(3y)-36.52%
ROA(5y)-32.04%
ROE(3y)-56.82%
ROE(5y)-44.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.64%
GM growth 5Y-15.56%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 5.68
Debt/EBITDA N/A
Cap/Depr 43.15%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.49
Altman-Z -5.34
F-Score7
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)49.02%
Cap/Depr(5y)92.75%
Cap/Sales(3y)2.21%
Cap/Sales(5y)13.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y44.75%
EPS Next 2Y22.07%
EPS Next 3Y16.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.37%
Revenue growth 3Y203.02%
Revenue growth 5Y151.62%
Sales Q2Q%-22.64%
Revenue Next Year-18.14%
Revenue Next 2Y-6.88%
Revenue Next 3Y-3.1%
Revenue Next 5YN/A
EBIT growth 1Y37.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.19%
EBIT Next 3Y32.72%
EBIT Next 5YN/A
FCF growth 1Y166.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y256.97%
OCF growth 3YN/A
OCF growth 5YN/A